Alembic Pharmaceuticals APLLTD
US generics (oral solids, injectables, oncology, derma) with India branded formulations and APIs
Mapped in 1 theme: Pharmaceuticals.
Where Alembic Pharmaceuticals sits in the supply chain
Alembic Pharmaceuticals appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Pharmaceuticals › Sterile injectables & fill-finish
Emerging entrantOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 6,229 | 6,672 | 7,345 |
| Net profit | 616 | 582 | 671 |
Latest-year revenue ₹7,345 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Large US approval count with new injectable/oncology capacity now built
- India branded and API businesses add stability
- Big capex cycle largely complete - operating leverage ahead if utilisation rises
Risks
- New plants carry depreciation before they fill, holding ROCE down
- US price erosion in oral solids
- Stock derated in the five years to Oct 2026
Common questions
What does Alembic Pharmaceuticals do?
US generics (oral solids, injectables, oncology, derma) with India branded formulations and APIs.
Where does Alembic Pharmaceuticals sit in the supply chain?
Alembic Pharmaceuticals (NSE: APLLTD) is mapped in 2 supply-chain layers: Generics (US & export) (Pharmaceuticals) and Sterile injectables & fill-finish (Pharmaceuticals).
Who are Alembic Pharmaceuticals' peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Sun Pharmaceutical Industries and 6 more.
What is Alembic Pharmaceuticals' market cap and valuation?
As of 30 Oct 2026: market cap ₹15,677 Cr, P/E 21.0x, ROCE 12.6%, ROE 13.4%, dividend yield 1.50%.